Confidently Grow Your Pharmaceutical Litigation Firm.

Pharmaceutical litigation involves complex science, extensive expert testimony, and often multi-year timelines before resolution. Whether you're pursuing individual drug injury cases or participating in MDL proceedings, the capital demands are significant. Tortlink connects pharma litigation firms with lenders who understand the unique risk profile and timeline of these cases.

Expert Funding

Pharmaceutical cases require world-class scientific experts, toxicologists, and medical professionals. Capital ensures you can retain the best experts without compromising your firm's cash position.

MDL Participation

Active participation in MDL proceedings requires sustained investment, common benefit work, discovery costs, and bellwether trial preparation. Funding ensures you can contribute meaningfully and protect your position.

Medical Record Analysis

Large-scale pharma dockets require systematic medical record review across hundreds or thousands of claimants. Capital funds the intake teams, medical reviewers, and technology needed to process efficiently.

Long-Horizon Patience

Pharma cases can take 3–7+ years to resolve. Capital facilities structured for litigation timelines ensure you're never pressured to settle prematurely or abandon strong cases.

Docket Building

Fund marketing and intake campaigns to build your claimant base. In pharma litigation, larger dockets create more negotiating leverage and better per-case economics.

Risk Distribution

Spread your financial risk across your portfolio rather than being overexposed to any single pharma category. Capital diversity matches case portfolio diversity.

Understanding Pharmaceutical Litigation Litigation

Pharmaceutical litigation represents one of the highest-stakes areas of plaintiff law. When a drug causes unexpected harm, whether through undisclosed side effects, manufacturing defects, or fraudulent marketing practices, the resulting litigation can involve thousands of injured patients and billions of dollars in potential damages. Pharma cases are scientifically complex and typically require extensive expert testimony on causation, epidemiology, and toxicology. The litigation process often involves federal MDL consolidation, where hundreds of individual lawsuits are coordinated before a single judge for pretrial proceedings. Firms that participate actively in MDLs, contributing to common benefit work, funding discovery, and preparing bellwether trials, position themselves for the largest recoveries. But this participation requires sustained capital investment over years, making litigation financing essential for pharma litigation firms.

Proving causation in pharma cases requires world-class experts in toxicology, epidemiology, and pharmacology. Retaining these experts is expensive but essential for case success.

Pharmaceutical MDLs routinely take 5–10 years from initial filing to global resolution. Firms must sustain operations and case investment throughout this extended timeline.

New studies and FDA actions can dramatically shift the landscape of a pharma litigation mid-stream. Firms need the financial flexibility to adapt their strategy as the science evolves.

Pharmaceutical companies have virtually unlimited defense budgets. Plaintiff firms need adequate capital to match their investment in experts, discovery, and trial preparation.